Mezaton ampoules 1% 1 ml №10

Dosage form

Injection

Packaging

10 pieces

Mechanism of action

MESATON - alpha-adrenomimetic, vasoconstrictor, vasoconstrictor. Stimulates postsynaptic alpha adrenoreceptors.
Biotransformation in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys as metabolites. The action begins immediately after administration and lasts for 20 (after intravenous administration) - 50 minutes (with a s / c injection) - 1-2 hours (after a / m injection).
The heart rate decreases, the shock output increases, the SBP and DBP increase, the pulse reflexively decreases. OPSS is growing. Stimulates the brain and spinal cord. Reduces blood flow - renal, dermal, in the abdominal organs and limbs, increases - the coronary. It constricts the pulmonary vessels and increases the pressure in the pulmonary artery. As a vasoconstrictor, it has an anti-congestive effect: it reduces swelling and hyperemia of the nasal mucosa, the severity of exudative manifestations, restores free breathing; lowers pressure in the paranasal cavities and in the middle ear. It causes dilated pupils, normalizes intraocular pressure in open-angle glaucoma.

Indications and usage

Subdural and inhalation anesthesia (to maintain adequate levels of blood pressure and prolongation of subdural anesthesia), local anesthesia (as a vasoconstrictor), acute circulatory failure, anaphylaxis, neurogenic shock, hypotension, including orthostatic, paroxysmal supraventricular tachycardia, reperfusion arrhythmias (Berzold-Jarish reflex), priapism, secretory prerenal anuria, iritis, iridocyclitis.

Contraindications

Hypersensitivity and mesenteric arteries, prostatic hypertrophy, pregnancy, children (up to 15 years) and advanced age.

Dosage and administration

P / C, in / m, in / in the jet slowly or infusionally (at a rate of 60-120 ml / h).For IV injection, 10 mg is dissolved in 9 ml of water, for intravenous infusion 10 mg is added to 500 ml of a 0.9% solution of sodium chloride or 5% glucose. Mild hypotension - s / c 2-5 mg (1-10 mg); in / in 0.2 mg (0.1-0.5 mg), the interval between injections is at least 10-15 minutes. Severe hypotension and shock - in / in drip; The initial infusion rate of 0.1-0.18 mg / min, as the blood pressure stabilizes, the rate is reduced to 0.04-0.06 mg / min. Paroxysmal supraventricular tachycardia - in / in the jet, the initial dose of not more than 0.5 mg for 20-30 s, the dose is gradually increased by 0.1-0.2 mg, 1 mg no more. Before subdural anesthesia (for the prevention of arterial hypotension), 2-3 mg intramuscularly or 0.2 mg (maximally up to 0.5 mg) are injected intravenously 3-4 minutes before the procedure. For prolongation of subdural anesthesia - 2-5 mg is added to the anesthetic solution. As a vasoconstrictor with regional analgesia, it is added to the anesthetic solution at the rate of 1 mg per 20 ml.

Adverse reactions

Headache, agitation, anxiety, irritability, weakness, dizziness, hypertension, bradycardia, arrhythmia, pain in the heart, respiratory depression, oliguria, acidosis, pallor of the skin, tremor, paresthesia, local ischemia of the skin at the injection site, necrosis and scab formation hit in the tissue or s / c injection.

Drug interactions

Oxytocin, MAO inhibitors, tricyclic antidepressants, ergot alkaloids, sympathomimetics enhance the pressor effect, and the latter and - arrhythmogenicity. Alpha-blockers (phentolamine), phenothiazines, Furosemide and other diuretics prevent vasoconstriction. Beta-adrenergic blockers level cardiac stimulating activity, against the background of reserpine arterial hypertension is possible (due to depletion of catecholamine stores in adrenergic neurons, sensitivity to sympathomimetics is increased).

Overdosage

Manifested by ventricular extrasystole and short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, a significant increase in blood pressure.

Treatment: in / in the introduction of alpha-blockers (eg, phentolamine) and beta-blockers (with rhythm disturbances).

Storage conditions

In the dark place at a temperature of no higher than 25 ° C